Stocks
Immunome Financial Statements (IMNM) |
||||||||||
| Immunomesmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2019 | 25.03.2021 | 28.03.2022 | 16.03.2023 | 28.03.2024 | 12.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 14.0 | 10.8 | |||
| Operating Income, bln rub | -10.3 | -12.3 | -25.2 | -36.9 | -109.5 | -271.6 | ||||
| EBITDA, bln rub | ? | -9.72 | -12.3 | -24.7 | -36.3 | -108.8 | -270.4 | |||
| Net profit, bln rub | ? | -10.6 | -17.1 | -24.5 | -37.5 | -106.8 | -262.6 | |||
| OCF, bln rub | ? | -9.60 | -12.1 | -18.2 | -28.7 | -7.57 | -60.6 | |||
| CAPEX, bln rub | ? | 0.233 | 0.586 | 0.079 | 0.248 | 0.831 | 4.89 | |||
| FCF, bln rub | ? | -9.83 | -12.7 | -18.3 | -28.9 | -8.40 | -65.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 10.3 | 12.3 | 25.2 | 36.9 | 122.8 | 281.2 | ||||
| Cost of production, bln rub | 0.615 | 0.755 | 0.755 | 0.631 | 0.728 | 1.36 | ||||
| R&D, bln rub | 8.82 | 7.49 | 14.1 | 23.3 | 103.2 | 255.8 | ||||
| Interest expenses, bln rub | 0.106 | 0.038 | 0.010 | 0.005 | 0.000 | 0.201 | ||||
| Assets, bln rub | 5.06 | 44.5 | 57.9 | 24.0 | 148.5 | 296.2 | ||||
| Net Assets, bln rub | ? | -35.6 | 41.3 | 48.2 | 16.7 | 119.9 | 253.8 | |||
| Debt, bln rub | 0.564 | 0.613 | 0.317 | 0.293 | 1.65 | 2.77 | ||||
| Cash, bln rub | 2.54 | 39.8 | 49.2 | 20.3 | 138.1 | 278.4 | ||||
| Net debt, bln rub | -1.98 | -39.2 | -48.9 | -20.0 | -136.5 | -275.6 | ||||
| Ordinary share price, rub | 9.68 | 13.0 | 2.21 | 10.7 | 2.50 | |||||
| Number of ordinary shares, mln | 5.74 | 3.39 | 11.5 | 12.1 | 19.8 | 59.9 | ||||
| Market cap, bln rub | 0 | 33 | 150 | 27 | 212 | 150 | ||||
| EV, bln rub | ? | -2 | -6 | 101 | 7 | 76 | -126 | |||
| Book value, bln rub | -36 | 41 | 48 | 17 | 120 | 254 | ||||
| EPS, rub | ? | -1.84 | -5.05 | -2.12 | -3.09 | -5.38 | -4.38 | |||
| FCF/share, rub | -1.71 | -3.75 | -1.59 | -2.39 | -0.42 | -1.09 | ||||
| BV/share, rub | -6.20 | 12.2 | 4.18 | 1.37 | 6.04 | 4.24 | ||||
| EBITDA margin, % | ? | -776.2% | -2 507% | |||||||
| Net margin, % | ? | -761.9% | -2 435% | |||||||
| FCF yield, % | ? | -38.8% | -12.2% | -108.0% | -3.96% | -43.7% | ||||
| ROE, % | ? | 29.6% | -41.4% | -50.8% | -225.3% | -89.1% | -103.4% | |||
| ROA, % | ? | -208.5% | -38.5% | -42.2% | -156.0% | -71.9% | -88.6% | |||
| P/E | ? | 0.00 | -1.92 | -6.11 | -0.71 | -1.99 | -0.57 | |||
| P/FCF | 0.00 | -2.58 | -8.17 | -0.93 | -25.3 | -2.29 | ||||
| P/S | ? | 15.1 | 13.9 | |||||||
| P/BV | ? | 0.00 | 0.79 | 3.10 | 1.61 | 1.77 | 0.59 | |||
| EV/EBITDA | ? | 0.20 | 0.52 | -4.07 | -0.19 | -0.70 | 0.47 | |||
| Debt/EBITDA | 0.20 | 3.19 | 1.98 | 0.55 | 1.25 | 1.02 | ||||
| R&D/CAPEX, % | 3 787% | 1 277% | 17 861% | 9 384% | 12 414% | 5 228% | ||||
| CAPEX/Revenue, % | 5.93% | 45.4% | ||||||||
| Immunome shareholders | ||||||||||
